Abstract
A critical goal of Alzheimer disease research is to identify disease biomarkers that can be used in clinical trials to assist in the adjudication of treatment effects. While clinical validation remains a goal for many potential Alzheimer disease biomarkers, the rapid proliferation of markers has sparked comparative efforts as well. New data acquisition methods and sophisticated image-processing algorithms are poised to make a substantial impact on our ability to make precise measurements of the structure and function of regions within the living human brain and their connections and chemical composition. This commentary provides a perspective on a recently published paper and how it illustrates progress and challenges in the field.
